We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

190 hedge funds and large institutions have $1.92B invested in ChemoCentryx, Inc. in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

204% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 25

153% more capital invested

Capital invested by funds: $761M → $1.92B (+$1.16B)

120% more call options, than puts

Call options by funds: $70M | Put options by funds: $31.8M

36% more funds holding

Funds holding: 140190 (+50)

12% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 52

Holders
190
Holders Change
+50
Holders Change %
+35.71%
% of All Funds
2.92%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
76
Increased
46
Reduced
52
Closed
25
Calls
$70M
Puts
$31.8M
Net Calls
+$38.2M
Net Calls Change
+$10.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$382M +$674K +19,194 +0.2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$186M +$8.98M +255,927 +5%
BlackRock
3
BlackRock
New York
$158M -$3.58M -102,067 -2%
State Street
4
State Street
Massachusetts
$97.1M -$67M -1,908,055 -42%
WA
5
Wasatch Advisors
Utah
$65.4M -$27.3M -778,173 -30%
BBA
6
Baker Bros. Advisors
New York
$59.4M +$46.7M +1,330,071 +442%
PAMS
7
Pictet Asset Management (Switzerland)
Switzerland
$58.5M +$56.4M +1,605,409 New
PA
8
Perceptive Advisors
New York
$51.5M +$30.4M +865,446 +157%
Millennium Management
9
Millennium Management
New York
$44.7M +$33.2M +946,776 +336%
Invesco
10
Invesco
Georgia
$44.4M +$5.79M +164,864 +16%
Norges Bank
11
Norges Bank
Norway
$40M +$26.1M +744,910 +210%
EAM
12
Eventide Asset Management
Massachusetts
$37.9M
FCM
13
Farallon Capital Management
California
$34.1M +$19.3M +549,463 +142%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$33.9M -$114K -3,250 -0.3%
Two Sigma Investments
15
Two Sigma Investments
New York
$30.5M +$26.5M +753,735 +910%
Marshall Wace
16
Marshall Wace
United Kingdom
$30.2M +$29.1M +828,998 New
SI
17
Sofinnova Investments
California
$26.6M +$7.5M +213,514 +41%
GKIM
18
GW&K Investment Management
Massachusetts
$23.7M +$22.9M +652,196 New
APM
19
Avidity Partners Management
Texas
$23.5M +$22.6M +644,400 New
Citadel Advisors
20
Citadel Advisors
Florida
$19.7M -$14.7M -419,075 -44%
Goldman Sachs
21
Goldman Sachs
New York
$19.6M +$14.4M +408,850 +318%
Northern Trust
22
Northern Trust
Illinois
$19M -$772K -21,978 -4%
TCM
23
Tang Capital Management
California
$18.2M
Wellington Management Group
24
Wellington Management Group
Massachusetts
$17.8M +$17.1M +487,909 New
TLP
25
Tri Locum Partners
New York
$15.9M +$14.8M +420,255 +2,619%

CCXI Hedge Fund Activity: Q4 2021 in Review

190 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q4 2021, worth a combined $1.92B — up 153% from $761M a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new CCXI positions and 25 closed out — a net gain of 51 holders — while 46 added to existing stakes and 52 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $56.4M. The largest seller was State Street, cutting an estimated $67M.

  • 190 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q4 2021, up from 140 in Q3 2021.
  • Funds reported $1.92B of ChemoCentryx, Inc. stock for Q4 2021, up 153% quarter-over-quarter.
  • 76 funds opened new ChemoCentryx, Inc. positions in Q4 2021 and 25 closed out, a net change of +51 holders.
  • The largest ChemoCentryx, Inc. buyer in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $56.4M added.
  • The largest ChemoCentryx, Inc. seller in Q4 2021 was State Street, an estimated $67M sold.

Based on aggregated 13F filings for Q4 2021.